Literature DB >> 12086972

Soluble guanylate cyclase: an old therapeutic target re-visited.

Adrian J Hobbs1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12086972      PMCID： PMC1573404          DOI： 10.1038/sj.bjp.0704779

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  17 in total

1.  NO-independent stimulators of soluble guanylate cyclase.

Authors:  A Straub; J P Stasch; C Alonso-Alija; J Benet-Buchholz; B Ducke; A Feurer; C Fürstner
Journal:  Bioorg Med Chem Lett       Date:  2001-03-26       Impact factor: 2.823

2.  NO-independent regulatory site on soluble guanylate cyclase.

Authors:  J P Stasch; E M Becker; C Alonso-Alija; H Apeler; K Dembowsky; A Feurer; R Gerzer; T Minuth; E Perzborn; U Pleiss; H Schröder; W Schroeder; E Stahl; W Steinke; A Straub; M Schramm
Journal:  Nature       Date:  2001-03-08       Impact factor: 49.962

3.  Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies.

Authors:  Johannes-Peter Stasch; Cristina Alonso-Alija; Heiner Apeler; Klaus Dembowsky; Achim Feurer; Torsten Minuth; Elisabeth Perzborn; Matthias Schramm; Alexander Straub
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats.

Authors:  L Rothermund; A Friebe; M Paul; D Koesling; R Kreutz
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Mechanism of tolerance development to organic nitrates.

Authors:  P Needleman; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

6.  Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.

Authors:  M B Hussain; A J Hobbs; R J MacAllister
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

7.  Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies.

Authors:  Johannes-Peter Stasch; Klaus Dembowsky; Elisabeth Perzborn; Elke Stahl; Matthias Schramm
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

8.  The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death.

Authors:  B Beltrán; A Mathur; M R Duchen; J D Erusalimsky; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

9.  Tissue distribution of the human soluble guanylate cyclases.

Authors:  J Budworth; S Meillerais; I Charles; K Powell
Journal:  Biochem Biophys Res Commun       Date:  1999-10-05       Impact factor: 3.575

10.  NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272.

Authors:  E M Becker; C Alonso-Alija; H Apeler; R Gerzer; T Minuth; U Pleiss; P Schmidt; M Schramm; H Schröder; W Schroeder; W Steinke; A Straub; J P Stasch
Journal:  BMC Pharmacol       Date:  2001-12-28
View more
  13 in total

1.  Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

Authors:  Amrita Ahluwalia; Paul Foster; Ramona S Scotland; Peter G McLean; Anthony Mathur; Mauro Perretti; Salvador Moncada; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-23       Impact factor: 11.205

2.  Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases.

Authors:  Patricia Pellicena; David S Karow; Elizabeth M Boon; Michael A Marletta; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

Review 3.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

4.  Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approach.

Authors:  Michael Russwurm; Florian Mullershausen; Andreas Friebe; Ronald Jäger; Corina Russwurm; Doris Koesling
Journal:  Biochem J       Date:  2007-10-01       Impact factor: 3.857

Review 5.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

6.  Investigation of the role of nitric oxide/soluble guanylyl cyclase pathway in ascorbic acid-mediated protection against acute kidney injury in rats.

Authors:  Vaishali Koul; Anudeep Kaur; Amrit Pal Singh
Journal:  Mol Cell Biochem       Date:  2015-07-05       Impact factor: 3.396

7.  Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.

Authors:  Marc Chester; Gregory Seedorf; Pierre Tourneux; Jason Gien; Nancy Tseng; Theresa Grover; Jason Wright; Johannes-Peter Stasch; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-19       Impact factor: 5.464

8.  Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.

Authors:  Melanie Madhani; Andrew R Hall; Friederike Cuello; Rebecca L Charles; Joseph R Burgoyne; William Fuller; Adrian J Hobbs; Michael J Shattock; Philip Eaton
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-11       Impact factor: 4.733

9.  Role of cyclic GMP on inhibition by nitric oxide donors of human eosinophil chemotaxis in vitro.

Authors:  Sara M Thomazzi; Juliana Moreira; Sisi Marcondes; Gilberto De Nucci; Edson Antunes
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

10.  Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.

Authors:  Marc Chester; Pierre Tourneux; Greg Seedorf; Theresa R Grover; Jason Gien; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-22       Impact factor: 5.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.